Program News
News and stories about members of the UNC Lineberger Clinical Research Program
-
Race and geography linked to different risks of breast cancer treatment delays
A study led by Katherine Reeder-Hayes, MD, MBA, MS, found that Black patients and patients living in certain regions experience greater delays.
-
Cancer patient finds support from family, friends, health care community
A head and neck cancer diagnosis has created some stumbling blocks for John Erwin and his family, but he says they are now stronger than they were before. “Our family is as tight now as it’s ever been.”
-
Study identifies molecular differences between primary breast cancer and its metastases
A multi-institutional national study has identified unique molecular features responsible for the development and progression of metastatic breast cancer.
-
Immune system B-cells can help predict HER2-positive breast cancer treatment response
Researchers report specific immune system cells can help them determine whether HER2-positive breast cancer will respond to treatment.
-
Studies identify barriers between doctors and their patients that limit clinical trial enrollment for Black people with blood cancers
Shakira Grant, MBBS, the studies’ principal investigator, shared the findings during oral presentations at the annual meeting of the American Society of Hematology (ASH) in New Orleans.
-
Study identifies health care access barriers for older adults with multiple myeloma and their caregivers
A study led by UNC Lineberger’s Shakira Grant, MBBS, and colleagues found several barriers to high-quality cancer care for people with multiple myeloma and their caregivers.
-
UNC Lineberger and UNC researchers discuss latest research at American Society of Hematology Annual Meeting
UNC Lineberger researchers will present the latest findings from studies and lead educational sessions at the 64th American Society of Hematology Annual Meeting in New Orleans, Dec. 10-13.
-
UNC Lineberger researchers present findings at San Antonio Breast Cancer Symposium
UNC Lineberger researchers and colleagues will be presenting the latest findings from basic, translational and clinical studies at the 45th annual San Antonio Breast Cancer Symposium.
-
Genetic analysis of the most common type of bladder cancer in patients with metastatic disease yields guidance on treatment options
A genomic study of more than 200 people with the most common type of bladder cancer that has spread could help guide how the cancer would respond to immunotherapy.
-
Protein could help identify head and neck cancers that require less intensive treatment
Adding detection of immune cell protein SYNGR3 to current protocols could lead to a more reliable way of determining which patients with head and neck cancer need less intensive treatment.
-
UNC Lineberger pancreatic cancer researchers receive five-year, $4.6 million grants from National Cancer Institute
The NCI awarded $9.3 million in support of two five-year research projects from researchers in the UNC Lineberger Pancreatic Cancer Center of Excellence in partnership with other institutions.
-
Accurate assessment of heart rhythm can optimize chemotherapy use
Using the wrong mathematical formula to assess heartbeat rhythms may lead oncologists to inappropriately stop life-saving chemotherapy, according to research findings from UNC Lineberger scientists.
-
UNC Lineberger creates RNA Discovery Center
The UNC RNA Discovery Center, led by Chad Pecot, MD, will cultivate an inclusive community of scientists dedicated to investigating all aspects of RNA biology.
-
Hematologist focuses on multiple myeloma, amyloidosis
Sascha Tuchman, MD, MHS, specializes in hematology, and specifically multiple myeloma and amyloidosis. At UNC Lineberger, he collaborates with other UNC Lineberger clinicians and scientists, and works to cultivate the next generation of myeloma experts.
-
Bae-Jump elected co-chair of NCI uterine task force
Victoria Bae-Jump, MD, PhD, has been elected co-chair of the National Cancer Institute Gynecologic Cancers Steering Committee’s Uterine Task Force.